Agonist News and Research

RSS

AI-designed protein activates Notch signaling pathway to boost T-cell production

A new paper published today in Cell highlights how researchers have leveraged AI-based computational protein design to create a novel synthetic ligand that activates the Notch signaling pathway, a key driver in T-cell development and function.

1 Aug 2025

Which GLP-1 meds have the most side effects? Study of 60,000 Facebook posts gives answers

Researchers analyzed nearly 60,000 public Facebook posts to identify real-world adverse events linked to GLP-1 receptor agonist (GLP-1 RA) medications. Gastrointestinal symptoms were most common, while mental health concerns and tirzepatide-specific side effects were also flagged.

28 Jul 2025

Chinese study shows lasting weight loss after tirzepatide treatment

Obesity has become a global epidemic, contributing to a host of chronic health conditions such as type 2 diabetes, hypertension, and cardiovascular disease.

23 Jul 2025

Can one drug do it all? Reviewing the expanding clinical universe of GLP-1 agonists

Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide significant benefits for cardiovascular, kidney, liver, joint, and sleep-related diseases. These effects extend beyond weight loss, suggesting anti-inflammatory mechanisms with broad potential for managing chronic diseases.

22 Jul 2025

GLP-1 receptor agonists linked to lower dementia risk in type 2 diabetes

GLP-1 receptor agonists, a class of drug used to treat type 2 diabetes, likely trump the widely prescribed metformin for curbing dementia risk in people with the condition, finds the largest study of its kind, published in the open access journal BMJ Open Diabetes Research & Care.

22 Jul 2025

Study reveals key role of Egr-1 in controlling autoimmune diseases

Autoimmune diseases, like multiple sclerosis result when the body's immune system starts to attack its own cells. Regulatory T cells, a subtype of T cells play a critical role in suppressing these attacks.

14 Jul 2025

Melatonin receptor signaling counters sleep fragmentation-mediated infertility in T2DM

This new article publication from Acta Pharmaceutica Sinica B, discusses how melatonin receptor 1a alleviates sleep fragmentation-aggravated testicular injury in T2DM by suppression of TAB1/TAK1 complex through FGFR1.

12 Jul 2025

Exploring the roles of orphan nuclear receptors in MASLD pathogenesis

Metabolic dysfunction-associated steatotic liver disease (MASLD), affecting approximately 30% of the global population, represents a spectrum of liver disorders ranging from simple steatosis to metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, and cirrhosis.

12 Jul 2025

Egr-1 gene identified as crucial regulator of regulatory T cells in multiple sclerosis

Autoimmune diseases, such as multiple sclerosis (MS), inflammatory bowel disease (IBD), and rheumatoid arthritis (RA), affect millions of people worldwide.

11 Jul 2025

New analysis shows stopping antidepressants rarely leads to severe symptoms

The largest review of 'gold standard' antidepressant withdrawal studies to date has identified the type and incidence of symptoms experienced by people discontinuing antidepressants, finding most people do not experience severe withdrawal.

10 Jul 2025

Could serotonin supplements become the next hair loss treatment?

Researchers have shown that serotonin directly stimulates dermal papilla cells and promotes hair growth in lab-grown hair follicloids and human hair follicles. The findings suggest serotonin and related compounds could offer new avenues for treating hair loss, though safety and dosing challenges remain.

9 Jul 2025

Innovative genome editing approach could be the key to lifelong effective weight management

Weight-loss drugs have surged in popularity, promising rapid results with regular injections. Now, researchers from Japan report a way for the body to make its own weight-loss drugs, doing away with injections in favor of a one-time treatment.

9 Jul 2025

New study identifies factors linked to successful weight loss using GLP-1RAs

A study in Diabetes, Obesity and Metabolism has identified certain characteristics that might influence people's weight loss after taking prescription drugs called glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as semaglutide (sold under the brand names Ozempic and Wegovy).

9 Jul 2025

Tirzepatide tops the charts for blood sugar and weight loss in type 2 diabetes

A large network meta-analysis ranked eight GLP-1 receptor agonists for glycemic, weight, and safety outcomes in adults with type 2 diabetes. Tirzepatide demonstrated the greatest efficacy for glucose control and weight loss, while liraglutide offered the lowest hypoglycemia risk.

7 Jul 2025

Tirzepatide rewires appetite and slashes calorie intake in new obesity trial

A 6-week randomized trial found that tirzepatide significantly reduced energy intake, appetite, and cravings in adults with overweight or obesity, outperforming liraglutide and placebo. Brain imaging revealed that tirzepatide also lowered neural responses to high-fat, high-sugar food cues, offering mechanistic insight into its potent weight-loss effects.

25 Jun 2025

Once-monthly obesity injection shows double-digit weight loss in major clinical trial

Researchers found that once-monthly maridebart cafraglutide led to substantial weight loss and improved glycemic control in adults with obesity, with or without diabetes, in a phase 2 randomized trial. The drug demonstrated an acceptable safety profile and supports further study in phase 3 trials.

24 Jun 2025

Amycretin delivers unprecedented weight loss in early trial for obesity treatment

Once-weekly amycretin, a novel peptide activating GLP-1, amylin, and calcitonin receptors, produced rapid, substantial, and sustained weight loss in adults with overweight or obesity during a phase 1b/2a trial. The treatment was generally well tolerated, with mostly mild to moderate gastrointestinal side effects, supporting further investigation in larger, longer studies.

23 Jun 2025

New oral drug shows promise for type 2 diabetes and obesity without side effects

Lower blood sugar and increased fat burning – without negatively affecting appetite or muscle mass. These are some of the most promising effects of a new potential drug treatment for people with type 2 diabetes and obesity, according to a new study published in the journal Cell by researchers from Karolinska Institutet and Stockholm University.

23 Jun 2025

Diabetes medication shows promise in cutting migraine days by more than half

A diabetes medication that lowers brain fluid pressure has cut monthly migraine days by more than half, according to a new study presented today at the European Academy of Neurology (EAN) Congress 2025.

20 Jun 2025

New ACC guidance helps incorporate pharmacologic weight management strategies into cardiovascular care

The American College of Cardiology has issued a Concise Clinical Guidance (CCG) document to aid clinicians in the use of medication for weight management in patients where treatment may provide cardiovascular benefit.

20 Jun 2025

Agonist News and Research

AI-designed protein activates Notch signaling pathway to boost T-cell production

Which GLP-1 meds have the most side effects? Study of 60,000 Facebook posts gives answers

Chinese study shows lasting weight loss after tirzepatide treatment

Can one drug do it all? Reviewing the expanding clinical universe of GLP-1 agonists

GLP-1 receptor agonists linked to lower dementia risk in type 2 diabetes

Study reveals key role of Egr-1 in controlling autoimmune diseases

Melatonin receptor signaling counters sleep fragmentation-mediated infertility in T2DM

Exploring the roles of orphan nuclear receptors in MASLD pathogenesis

Egr-1 gene identified as crucial regulator of regulatory T cells in multiple sclerosis

New analysis shows stopping antidepressants rarely leads to severe symptoms

Could serotonin supplements become the next hair loss treatment?

Innovative genome editing approach could be the key to lifelong effective weight management

New study identifies factors linked to successful weight loss using GLP-1RAs

Tirzepatide tops the charts for blood sugar and weight loss in type 2 diabetes

Tirzepatide rewires appetite and slashes calorie intake in new obesity trial

Once-monthly obesity injection shows double-digit weight loss in major clinical trial

Amycretin delivers unprecedented weight loss in early trial for obesity treatment

New oral drug shows promise for type 2 diabetes and obesity without side effects

Diabetes medication shows promise in cutting migraine days by more than half

New ACC guidance helps incorporate pharmacologic weight management strategies into cardiovascular care

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News